Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CG Oncology, Inc. (CGON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CG Oncology CGON has moved into Phase 2 of its 18-phase Adhishthana cycle, a critical stage that often sets the tone for early bullish momentum. Within this phase, the stock transitions into what's called the Buddhi move period, where breakouts are more likely to unfold.
- Robust 24-month complete response ( CR ) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer ( NMIBC ) who are unresponsive to Bacillus Calmette Guerin ( BCG ) treatment - - 90% of 12-month responders remained disease free at 24 ...
- Robust 24-month complete response ( CR ) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer ( NMIBC ) who are unresponsive to Bacillus Calmette Guerin ( BCG ) treatment -- 90% of 12-month responders remained disease free at 24 ...
- Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer ( NMIBC ) -- One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines ...